Healthcare

💊 Glucosamine Warning for People With Early Cognitive Decline - A 65,000-patient Nature Metabolism analysis links glucosamine use to a 25% higher likelihood of Alzheimer's progression in those with mild cognitive impairment, a finding with immediate clinical relevance for one of the most widely used supplements in older adults. 💪 Retatrutide Sets a New Ceiling for What Metabolic Drugs Can Achieve - Lilly's triple agonist delivered an average 71-pound weight loss in Phase 3 while also reducing arthritis pain, establishing the drug as a potential platform therapy across metabolic and musculoskeletal aging simultaneously. 🥗 Oral GLP-1 Drugs Enter Their Most Competitive Phase Yet - Orforglipron beat oral semaglutide in a Lancet head-to-head trial and AstraZeneca's elecoglipron advanced to Phase 3 on 10.5% weight loss data, creating a three-way race for the oral metabolic drug market. 🤖 SLAMF6 Could Unlock Immunotherapy for Patients Who Have Run Out of Options - A Nature study identifies a self-activating T cell brake that suppresses immunity independently of tumors, opening a new class of cancer treatment targets for patients most likely to fail existing checkpoint inhibitors. ❤️ Sleep Apnea Cardiovascular Risk Now Has a Gut Target - The bile acid receptor FXR, operating through gut microbiome signaling, is now identified as a mediator of arterial plaque buildup during sleep apnea, a finding that may eventually lead to gut-directed prevention strategies for cardiovascular disease in this high-risk population.

🧠 Brain Plasticity Has No Age Ceiling — A 4,000-person, three-year UT Dallas study confirms cognitive performance can improve well into the 90s, making brain health a genuinely actionable target at every life stage. 🧠 Blood Cancer Mutations May Be a Missing Alzheimer's Mechanism — TET2, DNMT3A, and ASXL1 mutations in brain microglia create a destructive inflammatory environment in Alzheimer's tissue, opening a new door to both screening and repurposed cancer therapies. 🤖 A Vaccine Designed to End the Fentanyl Crisis — Scripps Research's cross-reactive fentanyl antibody platform blocks the drug before it reaches the brain and extends protection to designer analogs, with human trials already underway in 2026. 💪 GLP-1 Drugs Are Reducing Physical Activity, Not Increasing It — Fitbit data from ENDO 2026 shows step counts falling after GLP-1 initiation, making exercise counseling a critical and often missing element of metabolic treatment plans. 🥗 GLP-1 Drugs May Also Be Breast Cancer Prevention Tools — A 110,000-woman Penn Medicine cohort study found 30% lower breast cancer incidence in GLP-1 users, with a multisite prevention trial now being planned.